Costs and yields
The VanEck Pharmaceutical ETF, known as PPH, offers a higher dividend return with a 2.00% trailing yield, which is notably more than the 1.50% yield provided by the iShares Global Healthcare ETF, or IXJ. This difference underscores the potential for more consistent payouts when holding a concentrated portfolio of pharmaceutical firms. Additionally, the VanEck fund's expense ratio is more affordable at 0.36%, compared to 0.40% for the iShares ETF, which focuses on a broader range of healthcare companies.
Lower ownership costs are a significant advantage for investors in the VanEck fund. Over time, these small savings can accumulate, making a meaningful impact on the overall value of an investor's portfolio. In a low-interest-rate climate, where investors are actively seeking income-generating assets, the 0.53-point yield gap could provide an extra boost to returns.
Portfolio composition
VanEck's PPH takes a more concentrated approach, holding just 26 stocks all centered around the pharmaceutical industry. Its largest holding is Eli Lilly, which makes up nearly 20% of the fund's total assets at 19.93%. Other top holdings include Novartis at 10.45% and Merck at 9.49%. This high concentration provides a deep dive into the drug development space and related fields.
On the other hand, the iShares Global Healthcare ETF offers a broader investment spread across 110 companies. This includes a wide range of healthcare stocks such as Johnson & Johnson, which accounts for 7.10% of the fund, and AbbVie at 5.03%. By incorporating biotechnology, medical devices, and healthcare services, this fund gives investors a more comprehensive view of the sector, helping to minimize overdependence on any one company or sub-industry.
The launch dates of the two ETFs also contribute to their differing strategies. VanEck's PPH was established in 2011 and has always maintained a focus on pharmaceuticals. In contrast, iShares' IXJ was launched in 2001 and has grown to encompass the entire healthcare ecosystem. This distinction in timing and structure plays a key role in the unique value each ETF brings to investors.
Performance and risk
Over the past five years, the VanEck Pharmaceutical ETF has delivered stronger returns but at the expense of increased volatility. Despite its superior performance, the fund has experienced more significant drawdowns compared to the iShares ETF. This reflects the risks that come with investing in a smaller, more specialized group of companies, where outcomes are often closely tied to industry-specific events.
In contrast, the iShares Global Healthcare ETF has taken a more consistent approach, with less severe declines during market fluctuations. This stability is partially due to the inclusion of medical equipment and services companies, which typically behave differently than pure pharmaceutical stocks. Nasdaq analysts point out that this strategy spreads risk across various sub-industries like biotechnology, diagnostics, and healthcare services, making the fund more resilient during challenging market conditions.
VanEck's PPH maintains a tight focus on drugmakers, meaning its performance is heavily influenced by factors such as patent expirations, drug approvals, and pricing pressures. On the flip side, the iShares ETF's diverse holdings allow it to capture growth opportunities from multiple parts of the healthcare sector, thereby reducing the impact of issues within a single segment of the industry.
For investors, the key decision lies in choosing between a focused, higher-risk investment in pharmaceuticals or a broader, more conservative exposure across the entire healthcare sector. The VanEck ETF may be the right choice for those confident in the trajectory of drug development and the regulatory landscape, while the iShares ETF could better suit investors looking for long-term diversification across different healthcare sub-sectors.
Understanding these distinctions is crucial when determining which ETF better aligns with an investor's portfolio objectives. Whether an individual prefers a concentrated bet or a more widespread investment strategy can significantly influence which option is more suitable for their financial goals and risk tolerance.